» Articles » PMID: 23471034

Annual Incremental Health Benefit Costs and Absenteeism Among Employees with and Without Rheumatoid Arthritis

Overview
Date 2013 Mar 9
PMID 23471034
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the impact of rheumatoid arthritis (RA) on absence time, absence payments, and other health benefit costs from the perspective of US employers.

Methods: Retrospective regression-controlled analysis of a database containing US employees' administrative health care and payroll data for those who were enrolled for at least 1 year in an employer-sponsored health insurance plan.

Results: Employees with RA (N = 2705) had $4687 greater average annual medical and prescription drug costs (P < 0.0001) and $525 greater (P < 0.05) indirect costs (because of sick leave, short- and long-term disability, and workers' compensation absences) than controls (N = 338,035). Compared with controls, the employees with RA used an additional 3.58 annual absence days, including 1.2 more sick leave and 1.91 more short-term disability days (both P < 0.0001).

Conclusion: Employees with RA have greater costs across all benefits than employees without RA.

Citing Articles

Using the Functional Comorbidity Index with administrative workers' compensation data: Utility, validity, and caveats.

Sears J, Rundell S, Fulton-Kehoe D, Hogg-Johnson S, Franklin G Am J Ind Med. 2023; 67(2):99-109.

PMID: 37982343 PMC: 10824282. DOI: 10.1002/ajim.23550.


Disability and workers' compensation trends for employees with mental disorders and SUDs in the United States.

Brook R, Kleinman N, Beren I Ment Health Clin. 2021; 11(5):279-286.

PMID: 34621603 PMC: 8463001. DOI: 10.9740/mhc.2021.09.279.


Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020.

Orbai A, Reddy S, Dennis N, Villacorta R, Peterson S, Mesana L Clin Rheumatol. 2021; 40(12):4933-4942.

PMID: 34287723 PMC: 8599387. DOI: 10.1007/s10067-021-05839-9.


Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.

Rendas-Baum R, Kosinski M, Singh A, Mebus C, Wilkinson B, Wallenstein G Rheumatology (Oxford). 2017; 56(8):1386-1394.

PMID: 28460083 PMC: 5850117. DOI: 10.1093/rheumatology/kex087.


Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis.

Shafrin J, Ganguli A, Sanchez Gonzalez Y, Shim J, Seabury S J Manag Care Spec Pharm. 2016; 22(12):1472-1481.

PMID: 27882832 PMC: 10398269. DOI: 10.18553/jmcp.2016.22.12.1472.